ELEVANCE HEALTH INC (A58.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:A58 • US0367521038

277.5 EUR
-14.1 (-4.84%)
Last: Feb 9, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

4

Overall A58 gets a fundamental rating of 4 out of 10. We evaluated A58 against 29 industry peers in the Health Care Providers & Services industry. There are concerns on the financial health of A58 while its profitability can be described as average. A58 has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • A58 had positive earnings in the past year.
  • In the past year A58 had a positive cash flow from operations.
  • Each year in the past 5 years A58 has been profitable.
  • Each year in the past 5 years A58 had a positive operating cash flow.
A58.DE Yearly Net Income VS EBIT VS OCF VS FCFA58.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

1.2 Ratios

  • A58's Return On Assets of 4.66% is amongst the best of the industry. A58 outperforms 82.76% of its industry peers.
  • Looking at the Return On Equity, with a value of 12.90%, A58 is in the better half of the industry, outperforming 72.41% of the companies in the same industry.
  • With a Return On Invested Capital value of 5.39%, A58 perfoms like the industry average, outperforming 55.17% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for A58 is in line with the industry average of 6.49%.
Industry RankSector Rank
ROA 4.66%
ROE 12.9%
ROIC 5.39%
ROA(3y)5.09%
ROA(5y)5.45%
ROE(3y)14.2%
ROE(5y)15.16%
ROIC(3y)6.61%
ROIC(5y)7.03%
A58.DE Yearly ROA, ROE, ROICA58.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

1.3 Margins

  • With a decent Profit Margin value of 2.84%, A58 is doing good in the industry, outperforming 65.52% of the companies in the same industry.
  • A58's Profit Margin has declined in the last couple of years.
  • A58 has a Operating Margin of 4.07%. This is comparable to the rest of the industry: A58 outperforms 48.28% of its industry peers.
  • In the last couple of years the Operating Margin of A58 has declined.
Industry RankSector Rank
OM 4.07%
PM (TTM) 2.84%
GM N/A
OM growth 3Y-9.09%
OM growth 5Y-8.43%
PM growth 3Y-8.92%
PM growth 5Y-5.39%
GM growth 3YN/A
GM growth 5YN/A
A58.DE Yearly Profit, Operating, Gross MarginsA58.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2 4 6

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • A58 has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, A58 has less shares outstanding
  • A58 has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, A58 has an improved debt to assets ratio.
A58.DE Yearly Shares OutstandingA58.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M
A58.DE Yearly Total Debt VS Total AssetsA58.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B 100B

2.2 Solvency

  • A58 has a debt to FCF ratio of 10.10. This is a negative value and a sign of low solvency as A58 would need 10.10 years to pay back of all of its debts.
  • The Debt to FCF ratio of A58 (10.10) is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.71 indicates that A58 is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.71, A58 is in the better half of the industry, outperforming 75.86% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF 10.1
Altman-Z N/A
ROIC/WACC0.64
WACC8.45%
A58.DE Yearly LT Debt VS Equity VS FCFA58.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

2.3 Liquidity

Industry RankSector Rank
Current Ratio N/A
Quick Ratio N/A
A58.DE Yearly Current Assets VS Current LiabilitesA58.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • A58 shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.49%.
  • Measured over the past 5 years, A58 shows a small growth in Earnings Per Share. The EPS has been growing by 6.12% on average per year.
  • A58 shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.62%.
  • A58 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.32% yearly.
EPS 1Y (TTM)-8.49%
EPS 3Y1.27%
EPS 5Y6.12%
EPS Q2Q%-13.28%
Revenue 1Y (TTM)12.62%
Revenue growth 3Y8.34%
Revenue growth 5Y10.32%
Sales Q2Q%8.51%

3.2 Future

  • A58 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.74% yearly.
  • The Revenue is expected to grow by 2.60% on average over the next years.
EPS Next Y-13.28%
EPS Next 2Y-1.35%
EPS Next 3Y4.53%
EPS Next 5Y13.74%
Revenue Next Year-2.33%
Revenue Next 2Y0.27%
Revenue Next 3Y1.79%
Revenue Next 5Y2.6%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
A58.DE Yearly Revenue VS EstimatesA58.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 50B 100B 150B 200B
A58.DE Yearly EPS VS EstimatesA58.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20 40 60

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 10.93, the valuation of A58 can be described as reasonable.
  • Based on the Price/Earnings ratio, A58 is valued cheaper than 89.66% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of A58 to the average of the S&P500 Index (28.06), we can say A58 is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 12.61, the valuation of A58 can be described as correct.
  • 72.41% of the companies in the same industry are more expensive than A58, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 27.86. A58 is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 10.93
Fwd PE 12.61
A58.DE Price Earnings VS Forward Price EarningsA58.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • The rest of the industry has a similar Enterprise Value to EBITDA ratio as A58.
  • A58's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. A58 is more expensive than 62.07% of the companies in the same industry.
Industry RankSector Rank
P/FCF 23.09
EV/EBITDA 9.91
A58.DE Per share dataA58.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 200 400 600

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)1.79
EPS Next 2Y-1.35%
EPS Next 3Y4.53%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 2.07%, A58 has a reasonable but not impressive dividend return.
  • A58's Dividend Yield is a higher than the industry average which is at 1.61.
  • A58's Dividend Yield is comparable with the S&P500 average which is at 1.80.
Industry RankSector Rank
Dividend Yield 2.07%

5.2 History

  • The dividend of A58 is nicely growing with an annual growth rate of 12.16%!
Dividend Growth(5Y)12.16%
Div Incr Years0
Div Non Decr Years0
A58.DE Yearly Dividends per shareA58.DE Yearly Dividends per shareYearly Dividends per share 2021 2022 2023 2025 2026 1 2 3 4 5

5.3 Sustainability

  • 27.00% of the earnings are spent on dividend by A58. This is a low number and sustainable payout ratio.
  • A58's earnings are growing around the same pace than its dividend. As long as the earnings growth is kept the dividend growth is sustainable.
DP27%
EPS Next 2Y-1.35%
EPS Next 3Y4.53%
A58.DE Yearly Income VS Free CF VS DividendA58.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B
A58.DE Dividend Payout.A58.DE Dividend Payout, showing the Payout Ratio.A58.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

ELEVANCE HEALTH INC

FRA:A58 (2/9/2026, 7:00:00 PM)

277.5

-14.1 (-4.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)01-28
Earnings (Next)04-20
Inst Owners91.68%
Inst Owner ChangeN/A
Ins Owners0.14%
Ins Owner ChangeN/A
Market Cap61.67B
Revenue(TTM)199.13B
Net Income(TTM)5.66B
Analysts73.57
Price Target338.62 (22.03%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.07%
Yearly Dividend5.77
Dividend Growth(5Y)12.16%
DP27%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.74%
Min EPS beat(2)6.46%
Max EPS beat(2)21.02%
EPS beat(4)3
Avg EPS beat(4)7.33%
Min EPS beat(4)-2.26%
Max EPS beat(4)21.02%
EPS beat(8)6
Avg EPS beat(8)1.93%
EPS beat(12)9
Avg EPS beat(12)1.87%
EPS beat(16)12
Avg EPS beat(16)2.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.77%
Min Revenue beat(2)-2%
Max Revenue beat(2)0.45%
Revenue beat(4)3
Avg Revenue beat(4)1.05%
Min Revenue beat(4)-2%
Max Revenue beat(4)4.3%
Revenue beat(8)6
Avg Revenue beat(8)0.85%
Revenue beat(12)9
Avg Revenue beat(12)1.1%
Revenue beat(16)12
Avg Revenue beat(16)0.96%
PT rev (1m)-0.26%
PT rev (3m)-0.62%
EPS NQ rev (1m)2.66%
EPS NQ rev (3m)-3.07%
EPS NY rev (1m)-4.19%
EPS NY rev (3m)-14.07%
Revenue NQ rev (1m)-4.33%
Revenue NQ rev (3m)-4.2%
Revenue NY rev (1m)-5.6%
Revenue NY rev (3m)-6.49%
Valuation
Industry RankSector Rank
PE 10.93
Fwd PE 12.61
P/S 0.37
P/FCF 23.09
P/OCF 17.09
P/B 1.67
P/tB 16.9
EV/EBITDA 9.91
EPS(TTM)25.38
EY9.15%
EPS(NY)22.01
Fwd EY7.93%
FCF(TTM)12.02
FCFY4.33%
OCF(TTM)16.24
OCFY5.85%
SpS753.82
BVpS166.12
TBVpS16.42
PEG (NY)N/A
PEG (5Y)1.79
Graham Number308
Profitability
Industry RankSector Rank
ROA 4.66%
ROE 12.9%
ROCE 6.75%
ROIC 5.39%
ROICexc 5.85%
ROICexgc 10.18%
OM 4.07%
PM (TTM) 2.84%
GM N/A
FCFM 1.59%
ROA(3y)5.09%
ROA(5y)5.45%
ROE(3y)14.2%
ROE(5y)15.16%
ROIC(3y)6.61%
ROIC(5y)7.03%
ROICexc(3y)7.13%
ROICexc(5y)7.56%
ROICexgc(3y)13.02%
ROICexgc(5y)14.04%
ROCE(3y)8.29%
ROCE(5y)8.81%
ROICexgc growth 3Y-11.47%
ROICexgc growth 5Y-9.01%
ROICexc growth 3Y-9.05%
ROICexc growth 5Y-6.9%
OM growth 3Y-9.09%
OM growth 5Y-8.43%
PM growth 3Y-8.92%
PM growth 5Y-5.39%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover1.64
Health
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF 10.1
Debt/EBITDA 3.2
Cap/Depr 72.19%
Cap/Sales 0.56%
Interest Coverage 250
Cash Conversion 44.42%
Profit Quality 56.06%
Current Ratio N/A
Quick Ratio N/A
Altman-Z N/A
F-Score5
WACC8.45%
ROIC/WACC0.64
Cap/Depr(3y)78.87%
Cap/Depr(5y)77.78%
Cap/Sales(3y)0.68%
Cap/Sales(5y)0.71%
Profit Quality(3y)81.36%
Profit Quality(5y)97.25%
High Growth Momentum
Growth
EPS 1Y (TTM)-8.49%
EPS 3Y1.27%
EPS 5Y6.12%
EPS Q2Q%-13.28%
EPS Next Y-13.28%
EPS Next 2Y-1.35%
EPS Next 3Y4.53%
EPS Next 5Y13.74%
Revenue 1Y (TTM)12.62%
Revenue growth 3Y8.34%
Revenue growth 5Y10.32%
Sales Q2Q%8.51%
Revenue Next Year-2.33%
Revenue Next 2Y0.27%
Revenue Next 3Y1.79%
Revenue Next 5Y2.6%
EBIT growth 1Y-11.4%
EBIT growth 3Y-1.51%
EBIT growth 5Y1.02%
EBIT Next Year1.62%
EBIT Next 3Y13.19%
EBIT Next 5Y13.39%
FCF growth 1Y-29.25%
FCF growth 3Y-24.06%
FCF growth 5Y-19.97%
OCF growth 1Y-25.29%
OCF growth 3Y-20.06%
OCF growth 5Y-16.69%

ELEVANCE HEALTH INC / A58.DE FAQ

Can you provide the ChartMill fundamental rating for ELEVANCE HEALTH INC?

ChartMill assigns a fundamental rating of 4 / 10 to A58.DE.


What is the valuation status of ELEVANCE HEALTH INC (A58.DE) stock?

ChartMill assigns a valuation rating of 4 / 10 to ELEVANCE HEALTH INC (A58.DE). This can be considered as Fairly Valued.


What is the profitability of A58 stock?

ELEVANCE HEALTH INC (A58.DE) has a profitability rating of 5 / 10.


Can you provide the expected EPS growth for A58 stock?

The Earnings per Share (EPS) of ELEVANCE HEALTH INC (A58.DE) is expected to decline by -13.28% in the next year.


Is the dividend of ELEVANCE HEALTH INC sustainable?

The dividend rating of ELEVANCE HEALTH INC (A58.DE) is 6 / 10 and the dividend payout ratio is 27%.